Skip Navigation


Annals of Oncology Advance Access originally published online on May 22, 2009
Annals of Oncology 2009 20(8):1439-1444; doi:10.1093/annonc/mdp004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/8/1439    most recent
mdp004v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Grosso, F.
Right arrow Articles by Casali, P. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grosso, F.
Right arrow Articles by Casali, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

sacromas and melanoma

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series

F. Grosso1,*, R. Sanfilippo1, E. Virdis2, C. Piovesan1, P. Collini2, P. Dileo1, C. Morosi3, J. C. Tercero4, J. Jimeno4, M. D'Incalci5, A. Gronchi6, S. Pilotti2 and P. G. Casali1

1 Adult Sarcoma Medical Treatment Unit, Cancer Medicine Department
2 Department of Pathology
3 Department of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
4 PharmaMar R&D, Madrid, Spain
5 Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan
6 Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

* Correspondence to: Dr F. Grosso, Adult Sarcoma Medical Treatment Unit, Fondazione IRCCS "Istituto Nazionale Tumori", Via G. Venezian 1, 20133 Milan, Italy; E-mail: federica.grosso{at}istitutotumori.mi.it

Background: Trabectedin has been approved in Europe as second-line therapy for advanced soft tissue sarcomas. A previous analysis showed that myxoid liposarcomas (MLS) are particularly sensitive to the drug. We report on the long-term efficacy of trabectedin in a subgroup of that series.

Methods: Since September 2002, 32 advanced pretreated MLS patients received trabectedin at our center. Data were reviewed focusing on their long-term outcome.

Results: Trabectedin was given as a 24-h continuous infusion every 21 days. A total of 376 and a median of 12 courses per patient (range 2–26; interquartiles range (IQR) 8–15) were delivered. Response rate per RECIST was 50% [95% confidence interval (CI) 32% to 68%], median progression-free survival (PFS) was 17 months (95% CI 13.5–30.1) and median overall survival is still not reached. In 10 patients, therapy was stopped in the absence of any evident disease, mostly after complete surgery of residual lesions. In these 10 patients, at a median follow-up of 25 months, PFS was 28.1 months (95% CI 25.6–36.4) from treatment start.

Discussion: These data indicate that the high response rate of MLS to trabectedin translates into prolonged PFS. Surgery of residual metastatic disease is already used quite extensively in metastatic MLS. Trabectedin may give further significance to this kind of surgery.

Key words: liposarcoma, myxoid liposarcoma, round-cell liposarcoma, trabectedin

Received for publication December 12, 2008. Accepted for publication December 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.